Stonepine Capital Management LLC purchased a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned 2.89% of PolyPid at the end of the most recent reporting period.
Separately, Rosalind Advisors Inc. grew its holdings in shares of PolyPid by 62.9% during the 3rd quarter. Rosalind Advisors Inc. now owns 679,168 shares of the company’s stock worth $2,336,000 after acquiring an additional 262,368 shares during the period. 26.47% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
PYPD has been the topic of a number of research analyst reports. Craig Hallum initiated coverage on PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of PolyPid in a report on Wednesday, October 2nd.
PolyPid Stock Up 0.3 %
Shares of PolyPid stock traded up $0.01 during midday trading on Wednesday, hitting $3.52. The company had a trading volume of 3,883 shares, compared to its average volume of 6,593. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.00. The company has a 50 day moving average of $3.48 and a 200 day moving average of $3.74. PolyPid Ltd. has a 52-week low of $2.95 and a 52-week high of $9.20.
PolyPid Company Profile
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Featured Articles
- Five stocks we like better than PolyPid
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Trading Stocks: RSI and Why it’s Useful
- 2 Generic Drug Stocks Ready to Surge in 2025
Want to see what other hedge funds are holding PYPD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PolyPid Ltd. (NASDAQ:PYPD – Free Report).
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
